Cost‐effectiveness of swab versus tissue sampling for infected diabetic foot ulcers from the CODIFI2 randomised controlled trial
Authors:
- Chris BojkeCBChris Bojke
- Henrietta KonweaHKHenrietta Konwea
- E. Andrea NelsonENE. Andrea Nelson
- Sarah T. BrownSBSarah T. Brown
- Colin C. EverettCEColin C. Everett
- Angela OatesAOAngela Oates
- Michael BackhouseMBMichael Backhouse
- Howard CollierHCHoward Collier
- Rachael GilbertsRGRachael Gilberts
- Michelle M. ListerMLMichelle M. Lister
Open Access
- 27 February 2025
- journal article
- Published by Wiley in Diabetic Medicine
- Vol. 42 (5) , e15492
Abstract
Aims: To compare the cost‐effectiveness of wound swabbing versus tissue sampling for infected diabetic foot ulcers.Methods: This multi‐centre, Phase III, prospective, unblinded, two‐arm parallel group, randomised controlled trial compared clinical (reported elsewhere) and economic outcomes of swab versus tissue sampling over a 52–104 week period.Resource use was logged using case record forms and patient questionnaire at weeks 4, 12, 26, 39, 52 and 104, costed using laboratory and published sources from the UK NHS perspective, at 2021/2022 price‐year. EQ‐5D‐3L questionnaires issued at these time points were used to derive quality‐adjusted life‐years (QALYs).To account for imbalances such as age, a regression‐based approach was used to estimate survival, expected costs and QALYs between the sampling arms. Available case analysis (ACA) and multiple imputation methods were applied for self reported missing data, and ACA for researcher‐collected data (survival, hospitalisations and antibiotic use). Probabilistic sensitivity analysis was used to assess the uncertainty of economic results.Results: We recruited 149 participants (75 swab, 74 tissue) from 21 UK sites, between 07 May 2019 and 28 April 2022 (last follow‐up 28 April 2023). Planned sample size was 730 participants, for 90% power to detect 12.5% difference in healing at 52 weeks, but the trial stopped early due to low recruitment.Expected QALYs in the swab‐sampling arm were greater than in the tissue‐sampling arm at weeks 26, 52 and 104.The cost of tissue sampling was greater than of swabbing when including antibiotics and hospitalisation. Swab sampling participants had higher QALYs and lower costs across weeks 26–52, reducing slightly by week 104.Conclusions: Because of higher costs, lower QALYs and lack of evidence of benefit, potentially due to the trial being underpowered, tissue sampling was dominated by wound swabbing in the cost‐effectiveness analysis.Keywords
Funding Information
- National Institute for Health and Care Research
This publication has 13 references indexed in Scilit:
- Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)Clinical Infectious Diseases, 2024
- IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes‐related foot infections (IWGDF/IDSA 2023)Diabetes/Metabolism Research and Reviews, 2023
- The cost of diabetic foot ulcers and amputations to the National Health Service in EnglandDiabetic Medicine, 2019
- Prognosis of the infected diabetic foot ulcer: a 12‐month prospective observational studyDiabetic Medicine, 2017
- Diabetic Foot Ulcers and Their RecurrenceNew England Journal of Medicine, 2017
- Deep tissue biopsy vs. superficial swab culture, including microbial loading determination, in the microbiological assessment of Skin and Soft Tissue Infections (SSTIs)Journal of Chemotherapy, 2016
- Diabetic foot infections: Current treatment and delaying the ‘post‐antibiotic era’Diabetes/Metabolism Research and Reviews, 2016
- A Comparison of Tissue versus Swab Culturing of Infected Diabetic Foot WoundsInternational Journal of Endocrinology, 2016
- Comparison of chronic wound culture techniques: swab versus curetted tissue for microbial recoveryBritish Journal of Community Nursing, 2014
- Corrected group prognostic curves and summary statisticsJournal of Chronic Diseases, 1982